)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Immatics
Immatics (IMTX) investor relations material
Immatics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary18 Aug, 2026
Executive summary
Enrollment in the SUPRAME Phase 3 trial for anzu-cel remains on track, with final PFS analysis expected in H1 2027 and BLA submission planned for 2027.
Updated Phase 1b data for anzu-cel in metastatic melanoma showed 56% confirmed ORR, 14.6 months mDOR, 6.1 months mPFS, and 16.2 months mOS, with a 2-year OS rate of 46%.
IMA203CD8 demonstrated 63% ORR and 50% confirmed ORR in gynecologic cancers, supporting broad applicability across solid tumors.
IMA402 bispecific therapy advanced to Phase 1b, with data across multiple cancers to be presented at ESMO Congress 2026.
Cash position of $448.2 million as of June 30, 2026, with cash reach projected into 2028.
Financial highlights
Cash and cash equivalents plus other financial assets totaled $448.2 million as of June 30, 2026, down from $534.7 million at year-end 2025.
Revenue for Q2 2026 was $10.4 million, up from $5.4 million in Q2 2025, driven by increased collaboration activity.
R&D expenses rose to $71.1 million in Q2 2026 from $51.4 million in Q2 2025, mainly due to clinical trial advancement.
Net loss for Q2 2026 was $71.2 million, an improvement from $80.1 million in Q2 2025, primarily due to lower non-cash FX losses and higher revenue.
Outlook and guidance
SUPRAME Phase 3 trial enrollment to complete by year-end 2026, with topline PFS data in H1 2027.
BLA submission for anzu-cel planned for 2027, with commercial infrastructure preparations underway.
Additional data from IMA203CD8 and IMA402 expected at ESMO Congress 2026; first combination data for IMA402/IMA401 in sqNSCLC anticipated in 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Immatics
- IMA203 demonstrated strong and durable responses in advanced melanoma with manageable safety.IMTX
Clinical Data Presentation - Q1 2026 net loss of $66.5M, $521.5M cash, and key PRAME clinical milestones set for 2026.IMTXQ1 2026
- PRAME cell therapy pipeline advanced, revenue fell, and cash runway extended to 2028.IMTXQ4 2025
- Biotech seeks up to $500M for TCR immunotherapy R&D, with $150M at-the-market via Leerink Partners.IMTXRegistration Filing
- Advanced PRAME therapies and bispecifics, but higher R&D costs led to a larger net loss.IMTXQ3 2025
- PRAME-targeted therapies deliver robust, durable responses and are advancing toward broad commercialization.IMTXInvestor Presentation
- IMA402 and IMA401 bispecifics show strong safety and efficacy in advanced solid tumors.IMTXStudy Update
- A 54% response rate and 6-month median PFS were achieved in advanced melanoma.IMTXStudy Update
- TCR-T therapy achieved 55% response in melanoma; pivotal trial and new data expected this year.IMTXJefferies 2024 Global Healthcare Conference
Next Immatics earnings date
Q3 202620 Nov, 2026
Immatics
Next Immatics earnings date
Q3 202620 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Immatics N.V. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of T cell redirecting immunotherapies aimed at treating cancer. The company's innovative approach combines the identification of true targets for cancer immunotherapies with the development of suitable T cell receptors. The company is headquartered in Tübingen, Germany, and its shares are listed on the Nasdaq.